Quantitative approaches to drug development
We provide consultancy services to help our clients reduce uncertainty in research and regulatory questions, increasing confidence in the development of new medicines that can improve patients’ lives. Science and Services
About
Pharmetheus reduces uncertainty in all phases of drug development.
News
This research focuses on leveraging quantitative modeling to support dose selection in oncology drug development, presenting development of an exposure-tumour growth inhibition (E-TGI) model to investigate the relationship between brigimadlin exposure and tumour shrinkage using data from a phase I clinical trial. The aim was to support the selection of the recommended phase II dose (RP2D) for brigimadlin, a potent…
Pharmetheus will be hosting satellite meetings at PAGE 2025 in Thessaloniki, Greece. These sessions will cover topics such as MIDD in regulatory interactions, physiologically-based translational modeling, and (R)TTE analysis. Sign up early to secure your spot and connect with our experts in a collaborative setting.
The findings demonstrate that crovalimab achieves complete terminal complement activity inhibition, provides effective disease control, and maintains a safety profile comparable to existing C5 inhibitors. Notably, the study also highlights crovalimab’s potential to reduce treatment burden, offering a promising avenue for improving care in PNH.
How we work
Traceability, accountability, and independent quality control are of utmost importance to us, and embedded in our way of working.
Publications
Explore our scientific publications.
Explore our web
Model Informed Drug Development (MIDD) consulting services
A quantitative framework to support and inform development program strategies and decisions.
“Sharing with colleagues is why I love working here”
Sophie Peigné supports clients with expert and strategic advice in pharmacometrics as well as hands-on modeling analyses for compounds in all development phases.
History of Pharmetheus
Our journey is an exciting one. We began as a start-up that spinned off from Uppsala University. Today, we have grown into a global medium-sized company, adding value to drug development each day.